Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis

Clinics and Research in Hepatology and Gastroenterology

Volumn 39, Issue 3, 2015, Pages 296-306

  Grigorian, Alla Y ^a   Mardini, Houssam E ^a   Corpechot, Christophe ^b,c   Poupon, Raoul ^b,c   Levy, Cynthia ^d  

^a UNIVERSITY OF KENTUCKY   (United States)

^b HÔPITAL SAINT ANTOINE   (France)

^c INSERM   (France)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BILIRUBIN; FENOFIBRATE; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN M;

ADJUVANT THERAPY; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CASE STUDY; DISEASE COURSE; DRUG RESPONSE; DRUG WITHDRAWAL; EFFECT SIZE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; META ANALYSIS; PRIMARY BILIARY CIRRHOSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; LIVER CIRRHOSIS, BILIARY; TREATMENT OUTCOME;

CHEMOTHERAPY, ADJUVANT; FENOFIBRATE; HUMANS; LIVER CIRRHOSIS, BILIARY; TREATMENT OUTCOME;

EID: 84930872144     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2015.02.011     Document Type: Article

References (31)

1. Parés A., Caballería L., Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006, 130(3):715-720.
2. Corpechot C., Chazouillères O., Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol 2011, 55(6):1361-1367.
3. Delerive P., Gervois P., Fruchart J.C., Staels B. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem 2000, 275(47):36703-36707.
4. Miyahara T., Schrum L., Rippe R., Xiong S., Yee H.F., Motomura K., et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 2000, 275(46):35715-35722.
5. Chanda D., Lee C.H., Kim Y.H., Noh J.R., Kim D.K., Park J.H., et al. Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner. Hepatology 2009, 50(3):880-892.
6. Honda A., Ikegami T., Nakamuta M. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology 2013, 57(5):1931-1941.
7. El-Sisi A., Hegazy S., El-Khateeb E. Effects of three different fibrates on intrahepatic cholestasis experimentally induced in rats. PPAR Res 2013, 781348. 10.1155/2013/781348.
8. Ghonem N.S., Ananthanarayanan M., Soroka C.J., Boyer J.L. Peroxisome proliferator-activated receptor (activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion). Hepatology 2014, 59(3):1030-1042.
9. Poupon R. Treatment of primary biliary cirrhosis with ursodeoxycholic acid, budesonide and fibrates. Dig Dis 2011, 29(1):85-88.
10. Cuperus F.J., Halilbasic E., Trauner M. Fibrate treatment for primary biliary cirrhosis. Curr Opin Gastroenterol 2014, 30(3):279-286.
11. Rudic J.S., Poropat G., Krstic M.N., Bjelakovic G., Gluud C. Bezafibrate for primary biliary cirrhosis. Cochrane Database Syst Rev 2012, 1:CD450091.
12. Assessment report for fenofibrate, bezafibrate, ciprofibrate and gemfibrozil containing medicinal product 2014, Accessed April 24 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Fibrates_31/WC500141411.pdf.
13. Moga C., Guo B., Schopflocher D., Harstall C. Development of a Quality Appraisal Tool for Case Series Studies Using a Modified Delphi Technique 2014, Institute of Health Economics, Edmonton AB, Accessed: March 14th, 2012. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
14. Recommendations on testing for funnel plot, asymmetry., Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. 2014, The Cochrane Collab85oration, Accessed April 10, 2014. http://handbook.cochrane.org/chapter_10/10_4_3_1_recommendations_on_testing_for%20funnel_plot_asymmetry.htm.
15. Hozo S.P., Djulbegovic B., Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005, 5:13.
16. Ohira H., Sato Y., Ueno T., Sata M. Fenofibrate treatment in patients with primary biliary cirrhosis. Am J Gastroenterol 2002, 97:2147-2149.
17. Nakamuta M., Enjoji M., Kotoh K., Shimohashi N., Tanabe Y. Long-term fibrate treatment for PBC. J Gastroenterol 2005, 40(5):546-547.
18. Dohmen K., Tanaka H., Haruno M. Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis. Fukuoka Igaku Zasshi 2013, 104(10):350-361.
19. Dohmen K., Mizuta T., Nakamuta M., Shimohashi N., Ishibashi H., Yamamoto K. Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol 2004, 10(6):894-898.
20. Walker L.J., Newton J., Jones D.E., Bassendine M.F. Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2009, 49:337-338.
21. Levy C., Peter J.A., Nelson D.R., Keach J., Petz J., Cabrera R., et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther 2010, 33:235-242.
22. Liberopoulos E.N., Florentin M., Elisaf M.S., Mikhailidis D.P., Tsianos E. Fenofibrate in primary biliary cirrhosis: a pilot study. Open Cardiovasc Med J 2010, 4:120-126.
23. Han X.F., Wang Q.X., Liu Y., You Z.R., Bian Z.L., Qiu de K., et al. Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy. J Dig Dis 2012, 13(4):219-224.
24. Poupon R. Personal communication 4/4/2014.
25. Lammers W.J., van Buuren H.R., Hirschfield G.M., Janssen H.L., Invernizzi P., Mason A.L., et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 2014, 147(6):1338-1349.
26. Kuiper E.M., Hansen B.E., de Vries R.A., den Ouden-Muller J.W., van Ditzhuijsen T.J., Haagsma E.B., et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009, 136(4):1281-1287.
27. Corpechot C., Abenavoli L., Rabahi N., Chrétien Y., Andréani T., Johanet C., et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008, 48(3):871-877.
28. Poupon R. Primary biliary cirrhosis: a 2010 update. J Hepatol 2010, 52(5):745-758.
29. Trivedi P.J., Lammers W.J., van Buuren H., Janssen H.L.A., Invernizzi P., Battezzati P.M., et al. Effective stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: results of a multi-centre international study. J Hepatol 2014, 60(1Suppl.):S55.
30. Komori A., Nakamura M., Aiba Y., Kugiyama-Yasunaga Y., Bekki S., Sasaki R., et al. Who may have treatment benefits with fibrates in primary biliary cirrhosis: a Single Center Retrospective Observational Cohort Analysis. J. Hepatol 2013, 58:S229-S407.
31. Lens S., Leoz M., Nazal L., Bruguera M., Parés A. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int 2014, 34(2):197-203.